"Prolonged Lung Cancer Screening Boosts Mortality Benefit" - Roxanna Nelson, RN, BSN
Extending lung cancer screening in individuals beyond five years can significantly impact the survival benefits associated with early disease detection, reports a new study published in the Annals of Oncology. "The study demonstrates the significance of lung cancer screening in defined high-risk groups," said, Fred Hirsch, MD, PhD, executive director of the center for thoracic oncology at The Tisch Cancer Institute at the Mount Sinai Health System who was not involved in the study. "The MILD study did not show any significant difference in mortality after five years. However after ten years, there was a difference in lung cancer and overall mortality. That is an important message and needs to be discussed."
— Fred Hirsch, MD, PhD, Executive Director, Center for Thoracic Oncology, Associate Director, Biomarker Discovery, The Tisch Cancer Institute, Professor, Medicine, Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai